HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Clinical trial NCT03685331 · COMPLETED

Trial details

NCT number: NCT03685331
Sponsor: Abramson Cancer Center at Penn Medicine
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Metastatic Breast Cancer Locally Advanced Breast Cancer Advanced Breast Cancer BRCA2 Mutation BRCA1 Mutation

Start date: 2020-10-15
Primary completion: 2025-08-01
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.